All in for ALL Mitigating VOD Risk in Patients Being Treated for R/R ALL
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: Support for this activity has been provided through an educational grant from Pfizer.
Upon completion of this activity, participants will be able to:
- Create optimal relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treatment plans in terms of treatment selection, sequencing, and dosing while incorporating patient point-of-care (inpatient vs outpatient);
- Incorporate strategies and tools to mitigate and manage veno-occlusive disease (VOD) risk in patients with R/R ALL proceeding to hematopoietic stem cell transplantation (HSCT);
- Outline tactics to facilitate interdisciplinary communication and decision making.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
WANT TO KNOW MORE?
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
The University of Texas
MD Anderson Cancer Center
Richard Larson, MD
The University of Chicago
Professor of Immunology
Chief, Division of Hematological Malignancies
Chief, Division of Cell Therapy
Director, Global Oncology, Duke Global Health Institute
Duke University Medical Center
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The University of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.